loading page

Insights from a rare myeloproliferative neoplasm with coexisting BCR-ABL1 fusion gene, CALR and TET2 mutations treated with nilotinib and ruxolitinib
  • +8
  • Li Huo,
  • Jundan Xie,
  • Qian Wang,
  • Hongjie Shen,
  • Zixuan Ding,
  • Lijun Wen,
  • Zhao Zeng,
  • Yi Xu,
  • Changgeng Ruan,
  • Suning Chen,
  • Mengxing Xue
Li Huo
First Affiliated Hospital of Soochow University

Corresponding Author:[email protected]

Author Profile
Jundan Xie
First Affiliated Hospital of Soochow University
Author Profile
Qian Wang
jiangsu institute of hematology
Author Profile
Hongjie Shen
First Affiliated Hospital of Soochow University
Author Profile
Zixuan Ding
First Affiliated Hospital of Soochow University
Author Profile
Lijun Wen
First Affiliated Hospital of Soochow University
Author Profile
Zhao Zeng
First Affiliated Hospital of Soochow University
Author Profile
Yi Xu
First Affiliated Hospital of Soochow University
Author Profile
Changgeng Ruan
Jiangsu institute of Hematology
Author Profile
Suning Chen
First Affiliated Hospital of Soochow University
Author Profile
Mengxing Xue
First Affiliated Hospital of Soochow University
Author Profile

Abstract

Myeloproliferative neoplasms (MPNs) with concurrent BCR-ABL1 fusion gene and CALR mutation are especially rare.We report a patient with coexisting BCR-ABL1 fusion gene, CALR and TET2 mutations who was treated with the combination of the second-generation TKI nilotinib and JAK1/JAK2 inhibitor ruxolitinib.
02 Jan 2022Submitted to Clinical Case Reports
04 Jan 2022Submission Checks Completed
04 Jan 2022Assigned to Editor
20 Jan 2022Reviewer(s) Assigned
27 Jan 2022Review(s) Completed, Editorial Evaluation Pending
04 Feb 2022Editorial Decision: Revise Minor
14 May 20221st Revision Received
01 Jun 2022Submission Checks Completed
01 Jun 2022Assigned to Editor
01 Jun 2022Review(s) Completed, Editorial Evaluation Pending
05 Aug 2022Editorial Decision: Revise Minor
04 Sep 20222nd Revision Received
06 Sep 2022Submission Checks Completed
06 Sep 2022Assigned to Editor
06 Sep 2022Review(s) Completed, Editorial Evaluation Pending
14 Dec 2022Editorial Decision: Accept